Welcome to our dedicated page for EVOMMUNE SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evommune, Inc. (NYSE: EVMN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer. As a public company, Evommune submits reports to the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events.
Among these documents are current reports on Form 8-K, such as the filing in which Evommune reported issuing a press release with a business update and financial results for a completed quarter. That press release, furnished as an exhibit and incorporated by reference, summarized the status of its lead programs EVO756 and EVO301, clinical milestones, collaboration revenue and cash position. Similar filings can help readers understand how the company presents its pipeline and operations to regulators and investors.
On this page, users can review Evommune’s periodic and current reports, including items that address results of operations and financial condition, risk factor discussions and descriptions of forward-looking statements. These filings often elaborate on topics such as clinical trial design and timing, potential market opportunities for chronic inflammatory disease therapies, and risks related to regulatory approval, competition, intellectual property and collaborations.
Stock Titan enhances access to these SEC documents with AI-powered summaries that highlight key points from long filings, helping users quickly identify sections on clinical programs, financial metrics and material events. The page also updates as new filings are submitted to the SEC’s EDGAR system, allowing investors and researchers to follow Evommune’s regulatory history, including current reports, registration statements and other relevant disclosures.
Evommune, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 2, 2026 at 11:30 a.m. Eastern Time. The proxy seeks election of two Class I directors, Luis Peña and Eugene A. Bauer, M.D., and ratification of BDO USA, P.C. as independent auditor for 2026.
Stockholders of record as of April 6, 2026 can attend and vote online using a 16-digit control number. The filing details board structure and independence, committee responsibilities, executive roles, and 2025 compensation, including salary, bonus and equity awards, as well as BDO’s 2025 audit fees.
Patel Jeegar Pravinkumar reported acquisition or exercise transactions in this Form 4 filing.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel received an employee stock option grant for 69,315 shares of common stock. The option has a strike price of $26.77 per share and expires on April 15, 2036, with no cash paid for the grant itself.
According to the vesting terms, one quarter of the option vests on the first anniversary of the grant date. The remaining three quarters vest in 36 equal monthly installments, contingent on Patel’s continuous service with the company. After this award, he holds 69,315 derivative securities directly.
Evommune, Inc. reported that Chief of Development Operations Janice Suzann Drew received an employee stock option grant covering 73,892 shares of common stock. The options carry an exercise price of $26.77 per share and expire on April 15, 2036.
According to the vesting terms, one fourth of the options will vest on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on continued service. Following this grant, the reporting person holds 73,892 stock options directly.
Evommune, Inc. reported that Chief Medical Officer Eugene Bauer received an award of employee stock options covering 51,117 shares of common stock. The options have an exercise price of $26.77 per share and expire on April 15, 2036.
One quarter of the options vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, contingent on his continued service. Following this grant, Bauer holds 51,117 derivative securities directly.
Evommune, Inc. reported that Chief Financial Officer Kyle Carver received an employee stock option grant. The award covers 98,946 shares of common stock at an exercise price of $26.77 per share and expires on April 15, 2036.
According to the vesting terms, one fourth of the option vests on the first anniversary of the grant, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to his continuous service. Following this grant, he holds 98,946 derivative securities directly.
Evommune, Inc. reported that Chief Business & Legal Officer Gregory S. Moss received an option grant for 115,279 shares of common stock at an exercise price of $26.77 per share. The options expire on April 15, 2036 and represent his entire reported option position from this grant.
According to the vesting terms, one fourth of the shares will vest on the first anniversary of the grant date, and the remaining shares will vest in 36 equal monthly installments thereafter, subject to his continuous service with the company.
Evommune, Inc. President & CEO Luis C. Pena received a grant of employee stock options covering 291,420 shares of common stock. The options have an exercise price of $26.7700 per share and expire on April 15, 2036. Following this grant, he holds 291,420 derivative securities related to this award.
According to the vesting schedule, one quarter of the options vests on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments, subject to his continuous service. This is a compensation-related award rather than an open-market purchase or sale.
Evommune, Inc. has filed a resale registration covering up to 4,494,279 shares of common stock that may be sold from time to time by existing selling stockholders. The company will not receive proceeds from these resales, though it previously raised capital by privately selling these shares at $27.88 each.
Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with Phase 2 programs EVO756 and EVO301 targeting conditions such as chronic spontaneous urticaria, atopic dermatitis, ulcerative colitis and migraine. As an emerging growth and smaller reporting company, it uses scaled reporting, retains earnings to fund growth and does not expect to pay dividends.
Evommune, Inc. furnished a webcast presentation describing the migraine treatment landscape and the scientific rationale for targeting the receptor MRGPRX2 with its oral small-molecule candidate EVO756. The materials outline how mast cells and sensory neurons may drive migraine and position MRGPRX2 inhibition as a potential new preventive approach.
The company highlights EVO756’s development roadmap across multiple inflammatory indications and its plan to initiate a Phase 2b, dose-ranging migraine prophylaxis trial in mid-2026. The presentation also notes high unmet need in migraine prevention, ongoing reliance on legacy preventives, and limitations of current CGRP-based therapies.